Janus Henderson Group PLC Raises Holdings in Eli Lilly and Company (NYSE:LLY)

Janus Henderson Group PLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 11.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,484,543 shares of the company’s stock after buying an additional 449,460 shares during the period. Eli Lilly and Company makes up about 1.8% of Janus Henderson Group PLC’s investment portfolio, making the stock its 9th largest holding. Janus Henderson Group PLC’s holdings in Eli Lilly and Company were worth $3,462,267,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. KKM Financial LLC lifted its stake in shares of Eli Lilly and Company by 13.1% in the fourth quarter. KKM Financial LLC now owns 3,327 shares of the company’s stock worth $2,568,000 after buying an additional 386 shares in the last quarter. Humankind Investments LLC lifted its position in Eli Lilly and Company by 29.1% in the 4th quarter. Humankind Investments LLC now owns 4,368 shares of the company’s stock valued at $3,372,000 after acquiring an additional 985 shares in the last quarter. Guardian Wealth Advisors LLC NC boosted its stake in Eli Lilly and Company by 1.3% during the 4th quarter. Guardian Wealth Advisors LLC NC now owns 4,782 shares of the company’s stock valued at $3,692,000 after purchasing an additional 63 shares during the last quarter. Ground Swell Capital LLC increased its holdings in shares of Eli Lilly and Company by 17.7% in the 4th quarter. Ground Swell Capital LLC now owns 345 shares of the company’s stock worth $266,000 after purchasing an additional 52 shares in the last quarter. Finally, Francis Financial Inc. raised its stake in shares of Eli Lilly and Company by 60.0% in the fourth quarter. Francis Financial Inc. now owns 888 shares of the company’s stock worth $686,000 after purchasing an additional 333 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.14% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on LLY shares. Guggenheim reiterated a “buy” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 price target for the company. Citigroup lowered their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and cut their target price for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Finally, Leerink Partners set a $950.00 price target on Eli Lilly and Company in a report on Friday, January 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $1,002.80.

Eli Lilly and Company Stock Down 2.0 %

LLY opened at $736.21 on Friday. The stock has a market cap of $697.73 billion, a price-to-earnings ratio of 62.87, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The firm’s fifty day moving average is $810.98 and its 200 day moving average is $810.88. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Eli Lilly and Company’s revenue was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.58 earnings per share. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.81%. Eli Lilly and Company’s payout ratio is 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.